The DYRK1A benzimidazole inhibitor DYR219 decreased Aβ42 aggregation and Tau phosphorylation, reversing cognitive deficits in 3xTg-AD mice that overexpress mutant APP K670M/N671L, MAPT P301L and Presenilin M146V46,51. This evidence concerns the gene MAPT and Alzheimer disease.